WATERTOWN, Mass .– (BUSINESS WIRE) – December 1, 2021–
SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing new treatments for multiple therapeutic areas, today announced that its Chinese initiative has been accepted by the Roche Accelerator. Launched earlier this year, the accelerator is Roche’s first internal accelerator in the world and reinforces its long-term commitment to Shanghai and China. The Chinese healthcare ecosystem is of growing global importance and offers a significant opportunity for patient impact. The collaboration with Roche Accelerator will support early strategic planning and potential China-based activities for the SQZ China initiative.
“We are delighted to be an early member of Roche Accelerator and to start working with its talented experts to support the strategic planning of this important global health center,” said Armon Sharei, Ph.D., CEO and founder of SQZ Biotechnologies and taken over by Min Dong, Ph.D., responsible for the SQZ China initiative. “China has significant patient needs in pathological areas where we are developing SQZ ™ cell therapies. We look forward to working with local stakeholders to explore the potential application of our cell therapy approach in China. “
Roche has been a strategic partner of the company since 2015 and has an ongoing collaboration with SQZ on the SQZ ™ APC Oncology Program globally.
About SQZ Biotechnologies
SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on harnessing the full potential of cell therapies for patients around the world and has active programs in oncology, autoimmune and infectious diseases, as well as additional exploratory initiatives for support the future growth of the pipeline. The company’s proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many cell types to design what we believe to be a wide range of potential therapies. With proven production times of less than 24 hours and the ability to eliminate preconditioning and long hospital stays, our approach could significantly expand the therapeutic range and accessibility of cell therapies. The company’s first therapeutic applications aim to generate targeted immune responses, both in activation for the treatment of solid tumors and infectious diseases, and in immune tolerance for the treatment of autoimmune diseases. For more information, please visit www.sqzbiotech.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained which do not relate to historical facts should be regarded as forward-looking statements, including without limitation , statements relating to events and presentations. , the development of our platform, product candidates, preclinical and clinical activities, progress and results, development plans, geographic expansion, clinical safety and efficacy, therapeutic impact and market opportunities . These forward-looking statements are based on the current expectations of management. Actual results could differ from those projected in forward-looking statements due to several risk factors. These factors include, among others, the risks and uncertainties associated with our limited operating history; our significant losses incurred since inception and our expectation of significant additional losses in the foreseeable future; the development of our first product candidates, on which our business is highly dependent; the impact of the COVID-19 pandemic on our operations and clinical activities; our need for additional financing and our cash flow path; the long, costly and uncertain process of clinical drug development, including uncertain clinical trial results and potential delays in regulatory approval; our ability to maintain our relationships with our third-party suppliers and strategic partners; and the protection of our proprietary technology, our intellectual property portfolio and the confidentiality of our trade secrets. These and other important factors discussed under the heading “Risk Factors” in our Annual Report on Form 10-K, as updated by our Quarterly Report on Form 10-Q for the quarterly period ended September 30 2021 and other documents filed with the US Securities and Exchange Commission, could cause actual results to differ materially from those indicated by forward-looking statements. All forward-looking statements represent management’s estimates as of that date and SQZ assumes no obligation to update such forward-looking statements, whether as a result of new information, the occurrence of current events, or otherwise, as a result of new information. unless required by law.
Certain information in this press release relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own internal research and estimates. While we believe these third-party sources are reliable as of the date of this press release, we have not independently verified and make no representations as to the adequacy, fairness, accuracy or completeness of any information obtained from third party sources. .
CONTACT: Investor Relations:
KEYWORD: CHINA UNITED STATES NORTH AMERICA ASIA PACIFIC MASSACHUSETTS
INDUSTRY KEYWORDS: STEM CELLS BIOTECHNOLOGY OTHER HEALTH PHARMACEUTICAL HEALTH ONCOLOGY OTHERS RESEARCH SCIENCE INFECTIOUS DISEASES SCIENCE CLINICAL TRIALS
SOURCE: SQZ biotechnology company
Copyright Business Wire 2021.
PUB: 12/01/2021 07:40 / DISC: 12/01/2021 07:41
Copyright Business Wire 2021.